All
A New Paradigm in mRNA Bioprocessing. How Ntensify™ Reshapes Affordability and Reduces Time-to-Market
Rabies mRNA Vaccine Download the case study as a pdf: Contact Us
Read MoreQuantoom Biosciences Prepares for the Implementation of the Ntensify™ Midi System by Afrigen Biologics’ in their GMP Facility, Paving the Way for African-Owned mRNA Vaccine Production
New agreement paves way for development of first African-owned COVID-19 vaccine.
Read MoreQuantoom Biosciences Collaborates with Stevanato Group to Elevate mRNA production with Nfinity™ Platform
New agreement paves way for development of first African-owned COVID-19 vaccine.
Read MoremRNA Production Reinvented
mRNA Production Reinvented Download the Corporate presentation as a pdf: Contact Us
Read MoreQuantoom Biosciences expands its offerings with Nplify, a high-quality linear DNA service for mRNA synthesis
New agreement paves way for development of first African-owned COVID-19 vaccine.
Read MoreQuantoom expands U.S. Market Reach with Key Appointments
New agreement paves way for development of first African-owned COVID-19 vaccine.
Read MoreQuantoom Biosciences installs the first Ntensify™ system for mRNA manufacturing at Afrigen Biologics in Cape Town
New agreement paves way for development of first African-owned COVID-19 vaccine.
Read MoreImmuneWatch, Quantoom Biosciences and UAntwerp join forces to explore new in vitro and in silico assays that predict T cell responses in vaccines
New agreement paves way for development of first African-owned COVID-19 vaccine.
Read MoreQuantoom Biosciences is growing in France with brand-new facilities for its DNA and enzymes activity located in Evry
New agreement paves way for development of first African-owned COVID-19 vaccine.
Read MoreRabies mRNA Vaccine
Rabies mRNA Vaccine Download the case study as a pdf: Contact Us
Read More